



MEDI-CAL DRUG USE REVIEW (DUR) BOARD

**State of California
DEPARTMENT OF HEALTH CARE SERVICES**

Notice is hereby given that the **Medi-Cal DUR Board** will conduct a public meeting on **Tuesday, May 12, 2015**, at the following location:

Xerox State Healthcare, LLC
840 Stillwater Road
Monterey Room
West Sacramento, CA 95605

Medi-Cal Drug Use Review Board
Meeting Agenda
May 12, 2015
9:30 AM-12:00 PM

Report Type*	Agenda Item	Presenter	Time
C	1. Welcome/Introduction	Pauline Chan, RPh, MBA	930-945
A	2. Call to Order/Review and Approval of Previous Minutes from February 17, 2015	Andrew Wong, MD	945-950
	3. Old Business		
A	a. Review of Action Items from Previous Board Meeting: <ul style="list-style-type: none"> i. Morphine milligram equivalency bulletin ii. Conflict of interest forms and bylaws updated, signed iii. Updates to Section 25 of DUR Manual iv. Educational outreach to providers: asthma v. Policy impact of requiring Medi-Cal prescribers to be registered in the Provider Master File vi. Concomitant use of anticholinergics and antipsychotics bulletin 	Pauline Chan, RPh, MBA	950-1000
	4. New Business		
R/A/D	a. Board Activities <ul style="list-style-type: none"> i. Reminder: DUR Board Elections in September ii. FFY2014 DUR Annual Report to CMS 	DUR Board Pauline Chan, RPh, MBA	1000-1010 1010-1040

R/A	<ul style="list-style-type: none"> b. Quarterly Report: 1Q2015 (January – March 2015) c. Review of Physician Administered Drugs (PADs): 4Q2014 (October – December 2014) d. Prospective DUR <ul style="list-style-type: none"> i. Review of DUR Alerts for New GCNs: 1Q2015 ii. Review of Prospective DUR Criteria: HIV Antiretroviral Medications and Ingredient Duplication (ID) iii. Review of Prospective DUR Criteria: Acetaminophen and High Dose (HD)/Ingredient Duplication (ID) e. Review of DUR Educational Outreach to Providers <ul style="list-style-type: none"> i. Proposal: Antipsychotic Metabolic Monitoring Letter f. Biennial Report: 2014 	Amanda Fingado, MPH	1040-1110
R/A/D	<ul style="list-style-type: none"> g. Retrospective DUR <ul style="list-style-type: none"> i. Update: Metformin, ACE Inhibitors/ARBs, Statins and Concomitant Use of Atypical Antipsychotics h. Review of DUR Publications <ul style="list-style-type: none"> i. DUR Educational Bulletin (March, 2015): Antipsychotic Use in Children and Adolescents ii. DUR Educational Alert (March, 2015): Varenicline and Alcohol Use iii. Discussion/Recommendations for Future Bulletins 	Shalini Lynch, PharmD	1110-1130
	<ul style="list-style-type: none"> i. Pharmacy Update <ul style="list-style-type: none"> i. Guidelines for the Use of Psychotropic Medications for Children and Youth in Foster Care ii. OIG Report: “Second-Generation Antipsychotic Drug Use Among Medicaid-Enrolled Children: Quality-of-Care Concerns” iii. ADURS Annual Meeting Summary 	Pauline Chan, RPh, MBA	1130-1155
C	5. Public Comments		1155-1200
	6. Consent Agenda		
I	<ul style="list-style-type: none"> a. Meeting feedback b. Next meeting: September 15, 2015 9:30 AM -12:00 PM DHCS Training Rooms B+C Sacramento, CA 95814 c. Proposed DUR Board Meeting Dates for 2015/2016: Tuesday, November 17, 2015 Tuesday, February 16, 2016 Tuesday, May 17, 2016 Tuesday, September 20, 2016 Tuesday, November 15, 2016 		
	7. Adjournment		1200

* REPORT TYPE LEGEND: **A: Action; R: Report; I: Information; C: Comment; D: Discussion**

** Comments from the public are always appreciated. However, comments will be limited to five minutes per individual.

Picture identification is required to gain access into the California Department of Health Services building. However, your security information will not be provided to the DUR Board.

You can obtain the DUR Board agenda from the Medi-Cal DUR Main Menu Web site (http://files.medi-cal.ca.gov/pubsdoco/dur/dur_home.asp).